C-P5VFsmall-molecule oral therapy, synapse protection, toxic oligomer blockade
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This is not investment advice. Please rely on your own due dilligence. The team at home school stocks has identified two stocks that could have profitable trade set ups for the August 13, 2025 trading day. Webtoon Entertainment Inc trades under Nasdaq symbol WBTN. The company recently released its Q 2 2025 Earnings call. Revenue was $348 million, up 8.5% year over year, driven by Paid Content, Advertising, and IP Adaptations. Net Loss was $3.9 million, a significant improvement from a $76.6 million loss in Q 2 2024, largely due to reduced IPO-related G&A expenses. The company has a cash position of over $581 million in cash & equivalents, plus $12 million in short-term deposits and no debt. The company experience growth across all three revenue streams: Paid content, IP adaptations, and Advertising. The company's strategic initiative with Disney could also bring Marvel, Star Wars, Disney Studios, and 20th Century Studios comics to WEBTOON’s mobile vertical-scroll format. Cogn
US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert: https://shorturl.at/RCZQU 🚀 Welcome to Benzinga's PreMarket Playbook! 🚀 Start Your Trading Day Right – Every Weekday at 8AM ET Join us as we break down key pre-market trends, top indicators, and actionable trading insights to help you stay ahead of the markets. Whether you’re a day trader, diving into options or futures, chasing penny stocks, or focused on blue chips, we’ve got real-time analysis and live discussions tailored to you! 📊 What to Expect: • Pre-Market Breakdown 🔍 • Actionable Trading Ideas 💡 • Expert Analysis & Insights 📈 ------------------------------------------------------------------------------------ 📈 Create your own Playbook ⬇️ 🔹 Get Monthly Picks of the Market's Fastest-Growing Stocks! ➡ https://www.benzinga.com/premium/ideas/benzinga-edge/?utm_source=bpytfg 🔹 Unlock High-Yield Investments, Curated by Experts ➡ https://www.benzinga.c
🚀 Welcome to Benzinga's PreMarket Playbook! 🚀 Start Your Trading Day Right – Every Weekday at 8AM ET Join us as we break down key pre-market trends, top indicators, and actionable trading insights to help you stay ahead of the markets. Whether you’re a day trader, diving into options or futures, chasing penny stocks, or focused on blue chips, we’ve got real-time analysis and live discussions tailored to you! 📊 What to Expect: • Pre-Market Breakdown 🔍 • Actionable Trading Ideas 💡 • Expert Analysis & Insights 📈 ------------------------------------------------------------------------------------ 📈 Create your own Playbook ⬇️ 🔹 Get Monthly Picks of the Market's Fastest-Growing Stocks! ➡ https://www.benzinga.com/premium/ideas/benzinga-edge/?utm_source=bpytfg 🔹 Unlock High-Yield Investments, Curated by Experts ➡ https://www.benzinga.com/premium/ideas/benzinga-edge/?utm_source=bpythy ------------------------------------------------------------------------------------ 🎙GUEST:
🚀 Welcome to Benzinga's PreMarket Playbook! 🚀 Start Your Trading Day Right – Every Weekday at 8AM ET Join us as we break down key pre-market trends, top indicators, and actionable trading insights to help you stay ahead of the markets. Whether you’re a day trader, diving into options or futures, chasing penny stocks, or focused on blue chips, we’ve got real-time analysis and live discussions tailored to you! 📊 What to Expect: • Pre-Market Breakdown 🔍 • Actionable Trading Ideas 💡 • Expert Analysis & Insights 📈 ------------------------------------------------------------------------------------ 📈 Create your own Playbook ⬇️ 🔹 Get Monthly Picks of the Market's Fastest-Growing Stocks! ➡ https://www.benzinga.com/premium/ideas/benzinga-edge/?utm_source=bpytfg 🔹 Unlock High-Yield Investments, Curated by Experts ➡ https://www.benzinga.com/premium/ideas/benzinga-edge/?utm_source=bpythy ------------------------------------------------------------------------------------ 🎙GUEST:
Advances in the Treatment of Alzheimer's & Other Cognitive Disorders Panel from the 7th Annual Neuroscience Innovation Forum Chaired by: Murali Gopalakrishnan, Global Head, Neuroscience Search & Evaluation, Corporate Strategy Office, AbbVie, Inc. Sumant Kulkarni, Managing Director, Biotechnology Equity Research, Canaccord Genuity LLC Panellists: Alexander Gebauer, CEO, Galimedix Jenny Laird, VP, Search & Evaluation Neuroscience, Eli Lilly and Company John Alam, Founder & CEO, CerovoMed Inc. Lisa Ricciardi, President & CEO, Cognition Therapeutics, Inc. Todd Haim, Director, Office of Strategic Extramural Programs, National Institute on Aging
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.
The Innovation Gap: Dissecting Emerging Modalities and Mechanisms for Treating CNS Diseases Working at the intersection of multiple fields, researchers are wielding a suite of new-age tools to diagnose and treat diseases of the brain. Those include digital health tools, remote patient monitoring and telemedicine technologies, as well as novel apps and AI-based approaches. This panel will feature experts from across these varied domains to discuss the latest trends in brain health. Moderators Ole Isacson, MD, PhD Director, Neuroregeneration Research Institute, McLean Hospital; Professor of Neurology and Neuroscience, HMS Charlie Yang, PhD Vice President, US Biopharmaceutical Equity Research Analyst, BofA Securities Panelists Lisa Ricciardi President & CEO, Cognition Therapeutics Kasper Roet, PhD CEO & Co-Founder, QurAlis Robert Scannevin, PhD Chief Scientific Officer, Verge Genomics
Cognition Therapeutics President & CEO Lisa Ricciardi joins Natalie Stoberman from the Proactive newsroom to discuss the company's unique focus on the treatment of Lewy body Dementia as well as other cognitive diseases like Alzheimer's Disease. Cognition Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The company is currently investigating its lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). #proactiveinvestors #cognitiontherapeutics #NASDAQ #CGTX #biopharma #alzheimersdisease #dementia #DLB #lewybodydementia #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
CT1812 is a small molecule sigma-2 receptor (S2R) modulator in development for Alzheimer’s disease (AD). Mary Hamby, PhD, and Lisa Ricciardi, CEO, Cognition Therapeutics Inc., Pittsburgh, PA, discuss the development of CT1812 and the evidence gathered to support its continued evaluation as a promising therapy for AD. First tested in a cortical neuronal culture system, CT1812 was shown to block toxic amyloid-beta (Aβ) oligomers from binding to neuronal synapses, restore trafficking deficits caused by oligomer accumulation, and protect synapses against damage. These findings were supported by studies in AD animal models that showed displacement of Aβ oligomers from synapses, reflected by increased Aβ in the cerebrospinal fluid. Improvements in cognition and memory deficits were also seen in rodents treated over several weeks. CT1812 has since completed three Phase I trials (SNAP, NCT03522129; SPARC, NCT03493282; and COG0102, NCT02907567) in which it was shown to be generally safe and tol
CT1812 is a small molecule sigma-2 receptor (S2R) modulator in development for Alzheimer’s disease (AD). Preclinical data from a cortical neuronal culture system and AD animal models have shown that CT1812 is able to displace amyloid-beta (Aβ) oligomers from synapses and prevent further receptor binding, thereby restoring damaged cellular processes such as autophagy and protein trafficking. Based on this mechanism of action, the team at Cognition Therapeutics wanted to see if S2R modulation could also block toxicity from alpha-synuclein (α-syn) oligomers. Preclinical testing demonstrated that CT1812 was able to block α-syn oligomers from binding to neuronal synapses, restore dysfunctional autophagy, and resolve protein trafficking deficits. CT1812 is therefore being investigated in the Phase II SHIMMER study (NCT05225415) in adults with dementia with Lewy bodies (DLB). This interview took place at the Alzheimer's Association International Conference (AAIC) 2022 in San Diego, CA.
Multi-center, randomized, double-blind, placebo-controlled, 6- month study in subjects with mild to moderate Dementia with Lewy Bodies.
This an open label study to assess the pharmacokinetics of CT1812 in normal healthy volunteers.
Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of \[C14\] CT1812
This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to moderate AD.
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).
This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD.
Study to Evaluate the Safety and Tolerability of Oral CT1812 in Subjects with Mild to Moderate Alzheimer's Disease.
This is Phase 1, single-center, open-label, single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of 4 probe drugs (tolbutamide, midazolam, dextromethorphan and omeprazole).
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease to evaluate the safety and tolerability of oral CT1812, administered for 28 days. This trial may include up to 8 qualified investigator sites in Australia.
This is a double-blind, placebo controlled, ascending dose, multi-cohort trial. The study will be conducted in two phases: a single ascending dose (SAD) phase "Part A", followed by a multiple ascending dose (MAD) phase "Part B". In Part A, subjects will receive one dose of study drug. In Part B, subjects within a cohort will receive the same dose daily for 14 days. In both parts, sequential cohorts will be exposed to increasing doses of CT1812 in order to identify the maximum tolerated dose (MTD).
The investigators will conduct a randomized placebo-controlled trial of a computerized intervention targeting cognition in 30 teens with autism spectrum disorder.
The purpose of this study is to determine the safety and efficacy of C105 in treating the cognitive deficits that can occur due to multiple sclerosis.
Associations between social connections and cognition: a global collaborative individual participant data meta-analysis Associations between social connections and cognition: a global collaborative individual participant data meta-analysis Lancet Healthy Longev . 2022 Nov;3(11):e740-e753. doi: 10.1016/S2666-7568(22)00199-4. Epub 2022 Oct 20. Authors Suraj Samtani 1 , Gowsaly Mahalingam 2 , Ben Chun Pan Lam 2 , Darren M Lipnicki 2 , Maria Fernanda Lima-Costa 3 , Sergio Luís Blay 4 , Erico Castro-Costa 3 , … gnitive decline. Funding: EU Joint Programme-Neurodegenerative Disease Research grant, funded by the National Health and Medical Research Council Australia, and the US National Institute on Aging of the US National Institutes of Health. Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved. Publication types Meta-Analysis Research Support, N.I.H., Extramural
Alpha Cognition Q1 2026 revenue rises, loss widens | ACOG Quarterly Report (10-Q) --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto … s Chief Executive Officer." Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors. foreign currency forward contracts financial "the Company enter … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company … #160; Interest income     506,056       461,869   Grant income     -       71,095   Gain from change in fair value of warrant liabilities     1,124,072       1,147,882   Other expenses     ( 11,919 )     ( 957 ) Total other income     1,618,209       1,679,889                     Net loss and c … 0; 29,770       7,282   Accrued expenditures for government grant     -       26,419   Gain from change in fair value of warrant liabilities     ( 1,124,072 )     ( 1,147,882 ) Change in fair value of bonus rights liability     ( 10,126 )     11,213   L
%PDF-1.6 %���� 42643 0 obj > endobj 44300 0 obj >/Filter/FlateDecode/ID[ ]/Index[42643 3400]/Length 1595/Prev 9795640/Root 42644 0 R/Size 46043/Type/XRef/W[1 3 1]>>stream h��Zͪ E���Ft��It#�>A^!ƍpŸ� ��;�u�{����JA���;�@T�!j�2�]30�����YD�͡�鮟s��[�������Yv�ϲ�a�O�1˓��|'ˇY���OY>�����y|�e^�;�|�Y>#��s��,�����-?�} ��_g���n��a�� >�*��VGwUb�����I"�V֤���5+��L՛ލ�R b�q���ޛy� 3wb��V��g6��ɺ�0������h2$���� >stream h��{yX�e��3H�$h����"Vdd�){e��PQ�3�� ���3� 0 �8*;��8 °���"�.%��R���y����?�����8�8���羯����A� 6�E �N�Ոg���g����L� �z���BM� �� {f�u���Y �kb� � X��� �V{��tXi�;�[m�G��D�
2021 Annual Report: The Power of Collaboration – Research Corporation for Science Advancement (RCSA) Skip to content RCSA Mission Staff Board of Directors Managing Your Grant Annual Reports News Cottrell Scholars Cottrell Scholar Award Holland Award IMPACT Award SEED Award STAR Award Dashboard Scialog Calendar Current Scialogs Completed Scialogs Becoming a Scialog Fellow Dashboard RCSA Fellows Be a Fellow Host a Fellow Contact Us RCSA June 17, 2022 2021 Annual Report: The Power of Collaboration For 110 years, RCSA has catalyzed transformative research by supporting innovative, cross-disc … ell Our History Foundation & Patents Archives Code of Conduct Managing Your Grant Contact Us Email List Contact Us Cottrell Scholars Fulbright-Cottrell Scholars Cottrell Scholar Award 2025 Cottrell Scholars 2024 Cottrell Scholars 2026 Cottrell Scholars 2023 Cottrell Scholars Cottrell Regional Meeting Awards Cottrell Scholar Conference Cottrell Scholars Collaborative Cottrell IMPACT Award Cottrell STAR Award Cottrell SEED Award FRED Awards Robert Holland Jr. Award About Ro
Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs | Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting OPS About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Ov … alents as of June 30, 2025 were approximately $11.6 million and total obligated grant funds remaining from the National Institute of Aging, a division of the National Institute of Health were $41.9 million. The Company estimates that it has sufficient cash to fund operations and capital expenditures into the second quarter of 2026. Research and development expenses were $11.5 million for the quarter ended June 30, 2025, compared to $11.6 million for the comparable period in 2 … lpar; NCT05531656 ) in early Alzheimer’s disease is ongoing with $81 million in grant support from the National Institute of Aging (NIA) at the National Institutes of Health. We believe zervimesine can regulate pathways that are impaired in these diseases though its interaction with the sigma-2 receptor, a mechanism that is functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be fou … t limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and ea … p; Grant income 7,106 7,311 12,192 12,223 Other income, net 141 333 355 577 Interest expense (3 )
%PDF-1.4 %���� 517 0 obj > endobj xref 517 27 0000000016 00000 n 0000002465 00000 n 0000002564 00000 n 0000002608 00000 n 0000002906 00000 n 0000003049 00000 n 0000003713 00000 n 0000004275 00000 n 0000004393 00000 n 0000004496 00000 n 0000004702 00000 n 0000004914 00000 n 0000005503 00000 n 0000006087 00000 n 0000006697 00000 n 0000007387 00000 n 0000007968 00000 n 0000008620 00000 n 0000009313 00000 n 0000009823 00000 n 0000050422 00000 n 0000050509 00000 n 0000052839 00000 n 0000053038 00000 n 0000053258 00000 n 0000082857 00000 n 0000000836 00000 n trailer ]/Prev 1015165>> startxref 0 %%EO … m 2026-05-01T11:42:26-04:00 2026-05-01T11:42:26-04:00 2026-04-30T18:10:30-06:00 application/pdf Form 10-K for Alpha Cognition INC filed 03/31/2026 Kaleidoscope - kscope.io 10-K filed 03/31/2026 Alpha Cognition INC 10-K uuid:8686a80e-0926-23bc-b4ca-057ffc7181f9 uuid:b0cc24d2-0dfa-4199-a519-507fd8b79dc6 endstream endobj 516 0 obj > endobj xref 0 517 0000000000 65535 f 0000094976 00000 n 0000095211 00000 n 0000095309 00000 n 0000096662 00000 n 0000096897 00000 n 0000096995 00000 … m 2026-05-01T11:42:26-04:00 2026-05-01T11:43:04-04:00 2026-05-01T11:43:04-04:00 application/pdf Form 10-K for Alpha Cognition INC filed 03/31/2026 Kaleidoscope - kscope.io 10-K filed 03/31/2026 Alpha Cognition INC 10-K uuid:8686a80e-0926-23bc-b4ca-057ffc7181f9 uuid:78ba98ae-58d8-4e27-84da-c75ec9abfd46 endstream endobj 516 0 obj > endobj 518 0 obj > endobj 544 0 obj > endobj 545 0 obj > endobj 546 0 obj >/Font >/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>> endobj 547 0 obj > endo
Firm | SBIR Skip to main content Skip to main content An official website of the United States government Here’s how you know Here’s how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites. Menu Contact Us Login Register Dashboard Login Please choose from one of the login options below: External User Login SBA Employee Login About Learn how … Archive Portfolio Interact with our SBIR/STTR portfolio’s data sets Portfolio - Award Data Portfolio - Company Data API Documentation Data Resources Data Dictionary Apply Better understand the application process and eligibility Apply Find Topics and Solicitations Frequently Asked Questions (FAQ) Lab to Market Hub Program Tutorials Community Stay connected with our innovation ecosystem Community Event Spotlight News and Events Newsletter Sign-up Federal and State Technology ( … vents Newsletter Sign-up Federal and State Technology (FAST) Growth Accelerator Fund Competition (GAFC) Company Portfolio Data Back to Company Search COGNITION THERAPEUTICS, INC. Address 2403 SIDNEY ST STE 261 PITTSBURGH, PA, 15203-5118 USA View website UEI: NUNHAKQ7MS86 Number of Employees: 14 HUBZone Owned: No Woman Owned: No Socially and Economically Disadvantaged: No SBIR/STTR Involvement Year of first award: 2010 7 Phase I Awards 5 Phase II Awards 71.43% Conversion Rate … ent awards are being displayed. To view all of this company's awards, visit the Award Data search page. Human AME study of CT1812, a small molecule in phase 2 clinical trials for the treatment of Alzheimer's disease Amount: $1,642,783 Topic: NIA PROJECT SUMMARY/ABSTRACT Alzheimerandapos;s disease (AD) afflicts nearly six million people in the United States (U.S), and this number is expected to double by 2050. Disease modifying medical therapies for AD continu … r elucidating the details of CT1812’s mechanism of action. This Fast-Tract SBIR proposal will provide crucial details about this novel mechanism of action and will enable the application of the proprietary portfolio of sigma-2 ligands at CogRx to other diseases. This information will increase the chance for partnering opportunities necessary for
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease | Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting OPS About Us About Us Management Team Board of Directors Advisory Boards Investors I … electrical impulses in the theta band. SEQUEL was supported by $5.3 million in grant awards (R01AG058710) by the National Institute of Aging (NIA) of the National Institutes of Health (NIH). Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of histo … t limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and ea … isors [email protected] Email Alerts Email I accept the Privacy Policy Submit Unsubscribe Loading... Linkedin-in X-twitter Terms of Use Privacy Policy Careers FCOI Policy Contact us Copyright© 2024 Cognition Therapeutics All rights reserved Scroll to Top Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. You are n
Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023 | Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting OPS About Us About Us Management Team Board of Directors Advisory Boards Inv … re not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data and pre-clinical studies bei … isors [email protected] Email Alerts Email I accept the Privacy Policy Submit Unsubscribe Loading... Linkedin-in X-twitter Terms of Use Privacy Policy Careers FCOI Policy Contact us Copyright© 2024 Cognition Therapeutics All rights reserved Scroll to Top Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. You are n
Publications – Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Overview Press Releases Events In The News Financial Information Stock Information Corporate Governance FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting Ops About Us About Us Management Team Board of Directors Advisory Boards Investors Overview Press Releases Events In The News Financial Information Stock Information Corporate Governance FAQs Pipeline Pipeline
Cognition Therapeutics initiates US clinical testing of CT1812, a novel small... Menu Advanced Structure search List search Wish Lists Cart Sign in Sign in For suppliers --> Contact us Catalog of Screening Compounds Screening Libraries Building Blocks Al/ML Data sets new 1B virtual space new Advanced Structure search List search Homepage > Company > Media > Pharma News > 2016 > Cognition Therapeutics initiates US clinical testing of CT1812, a novel small molecule for the potential treatment of Alzheimer's disease Cognition Therapeutics initiates US clinical testing of CT1812, a novel small … olunteers, 74 of whom received CT1812. Study COG0102 is supported in part under Award Number RF1AG054176 from the National Institute on Aging of the National Institutes of Health. About Cognition Therapeutics, Inc. Cognition Therapeutics (CogRx) is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer's d
Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023" | Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting OPS About Us About Us Management Team Board of Di … d to: competition, our ability to secure new (and retain existing) non-dilutive grant funding, our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; the timing, scope and likelihood of regulatory filings and approvals, including regula … isors [email protected] Email Alerts Email I accept the Privacy Policy Submit Unsubscribe Loading... Linkedin-in X-twitter Terms of Use Privacy Policy Careers FCOI Policy Contact us Copyright© 2024 Cognition Therapeutics All rights reserved Scroll to Top Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. You are n
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Cognition Therapeutics initiates US clinical testing of CT1812, a novel small... Menu Advanced Structure search List search Wish Lists Cart Sign in Sign in For suppliers --> Contact us Catalog of Screening Compounds Screening Libraries Building Blocks Al/ML Data sets new 1B virtual space new Advanced Structure search List search Homepage > Company > Media > Pharma News > 2016 > Cognition Therapeutics initiates US clinical testing of CT1812, a novel small molecule for the potential treatment of Alzheimer's disease Cognition Therapeutics initiates US clinical testing of CT1812, a novel small … olunteers, 74 of whom received CT1812. Study COG0102 is supported in part under Award Number RF1AG054176 from the National Institute on Aging of the National Institutes of Health. About Cognition Therapeutics, Inc. Cognition Therapeutics (CogRx) is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer's d
Events | Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting OPS About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipeline Pip … isors [email protected] Email Alerts Email I accept the Privacy Policy Submit Unsubscribe Loading... Linkedin-in X-twitter Terms of Use Privacy Policy Careers FCOI Policy Contact us Copyright© 2024 Cognition Therapeutics All rights reserved Scroll to Top Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. You are n
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
--> Cognition Therapeutics Reports Phase 2 Study Enrollment - CGTX | --> Login Start Free Trial Catalyst Calendar FDA Calendar Track key readouts and FDA decision dates in biotech and pharma. BPW Portfolio Bio Hedge Fund Shots and more... Historical FDA Calendar Review past FDA decisions and clinical readouts. Market Movers Track today's biotech market movers Biotech Earning Calendar Stay updated on biotech earnings. Historical PDUFA Dates Review past PDUFA dates and decisions. PDUFA Calendar Stay ahead of upcoming PDUFA dates Conference Calendar Keep up with biotech events. IPO Upcoming & … p; past IPOs. Bio Pharma Screener Catalyst Sync™ Track biotech catalysts. Hedge Fund Screener Analyze hedge fund holdings. Company Screener Holistic company & pipeline analysis. All Stocks Holdings Explore hedge fund stock data. Heat-Map Market size & sector heat map. Inside Trades Monitor insider trading. Biotech Analyst Ratings Biotech analyst ratings & price targets M&A Tracker Track M&A deals and acquisition targets Resources News Latest biotech news. … he trial this year. Lastly, we recently obtained the FDA's clearance on our IND application to pursue a Phase 2 study of CT1812 in 240 patients with geographic atrophy. Our extensive non-dilutive grant funding supports the majority of our trials. Taken together, we believe we are in a position to efficiently execute all of our set objectives across the business, and we look forward to delivering on our goals," concluded Ms. Ricciardi. Financial Highlights: Cognition Therapeut … balance was $41.6 million. The Company estimates that it has sufficient cash to fund operations and capital expenditures into the second half of 2024. For the year ended December 31, 2022, research and development expenses were $30.3 million compared to $18.6 million for 2021. The increase in the Company's R&D expenses for 2022 was primarily attributable to an increase in clinical programs related to increased Phase 2 trial activity, and an increase in associated personne … re not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies a
Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer | Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting OPS About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Fin … assachusetts. Mr. Doyle added, “Cognition is fortunate to have a strong base of grant awards from the National Institutes of Health to support many of its studies. As a clinical-stage biotech, the company will need to execute on a financial plan that fosters value creation and generates opportunity in various market conditions. I am looking forward to working with Cognition’s leadership, finance team and board as the company evolves.” About Cognition Therapeutics, Inc. Cognit … re not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data and pre-clinical studies bei … isors [email protected] Email Alerts Email I accept the Privacy Policy Submit Unsubscribe Loading... Linkedin-in X-twitter Terms of Use Privacy Policy Careers FCOI Policy Contact us Copyright© 2024 Cognition Therapeutics All rights reserved Scroll to Top Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. You are n
After you. Cognition and Health-Distribution Preferences --> --> --> Advanced search Economic literature: papers , articles , software , chapters , books . Authors Institutions Rankings Help/FAQ MyIDEAS More options at page bottom Economic literature Authors Institutions Rankings Help/FAQ MyIDEAS (now improved) --> Advanced search Browse Econ Literature Working papers Journals Software components Books Book chapters JEL classification More features Subscribe to new research RePEc Biblio Author registration Economics Virtual Seminar Calendar ConfWatcher NEW! Printed from https://ideas.repec.org
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account June 24, 2026 07:30 ET | Source: Cognition Therapeutics, Inc. Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes - Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease -- Company Developing NPI as a Measure of DLB Psychosis - PURCHASE, N.Y., June 24, 2026 ...
Cognition AI - Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Contents move to sidebar hide (Top) 1 Background 2 See also 3 References 4 External links Toggle the table of contents Cognition AI 1 language Ido Edit links Article Talk English Read Edit View history Tools Tools move to sidebar hide Actions Re … ; [ 6 ] [ 7 ] The company was backed by Peter Thiel 's Founders Fund which provided $21 million in early 2024, valuing the company at $350 million. [ 3 ] In April 2024, Founders Fund led a $175 million investment into Cognition valuing the company at $2 billion making it a unicorn . [ 2 ] [ 4 ] [ 8 ] In May 2024, it was announced that Cognition partnered with Microsoft to integrate Devin AI and would be powered by Microsoft Azur … il 24, 2024). "Six-Month-Old AI Coding Startup Valued at $2 Billion by Founders Fund" . The Information . ^ Gupta, Sukriti (May 24, 2024). "Microsoft Now has Both Kevin and Devin" . AIM . Archived from the original on May 25, 2024 . Retrieved May 25, 2024 . ^ Clark, Kate (March 18, 2025). "Cognition AI Hits $4 Billion Valuation in Deal Led by Lonsdale's Firm" . Bloomberg News . ^ "Cognition | Devin 2.0" . cognition.ai . April 3, 2025 . Retrieved April 3, 2025 . ^ "Cognition's … the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization. Privacy policy About Wikipedia Disclaimers Contact Wikipedia Legal & safety contacts Code of Conduct Developers Statistics Cookie statement Mobile view Search Search Toggle the table of contents Cognition AI 1 language
Association of Body Fat Distribution Patterns at MRI with Brain Structure, Cognition, and Neurologic Diseases Association of Body Fat Distribution Patterns at MRI with Brain Structure, Cognition, and Neurologic Diseases Radiology . 2026 Jan;318(1):e252610. doi: 10.1148/radiol.252610. Authors Miao Yu # 1 2 , Libin Yao # 3 , Sanjeev Shahi 1 , Yingqianxi Xu 1 , Meizi Li 1 , Qingtong Zheng 1 , Di Ma 1 , Qi Zhang 1 , Dan Wang 1 , Yang Wu 1 , Xiao Zho
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Stock Information | Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting OPS About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs P … isors [email protected] Email Alerts Email I accept the Privacy Policy Submit Unsubscribe Loading... Linkedin-in X-twitter Terms of Use Privacy Policy Careers FCOI Policy Contact us Copyright© 2024 Cognition Therapeutics All rights reserved Scroll to Top Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. You are n
Companies - Lux Capital - Science and Tech Venture Capital Companies People Riskgaming Mission contact Search Thank you! Your submission has been received! Oops! Something went wrong while submitting the form. suggestions Transportation Artificial Intelligence Companies “Securities” news People A-Alpha Bio “securities” This is some text inside of a div block. About Companies People Mission riskgaming Articles, Podcasts & Scenarios More Events Media Brand Assets contact us catalysts THESE ARE THE companies MAKING WHAT’S NEXT Explore Select lux portfolio companies Filters tag template Sort D … Civic Layer: Welcoming Zach Iscol to Lux Capital Unum Lux April 13, 2026 f(Lux) Fellowship 2026 Unum Lux March 31, 2026 We're Backing Crosby to End the Billiable Hour for Laywers Unum Lux February 21, 2026 Lux Q4 2025 Report Josh Wolfe January 7, 2026 Lux Capital Raises $1.5 billion for Fund Focused on New Science, Defense Bloomberg January 7, 2026 Announcing Lux Ventures IX Unum Lux November 20, 2025 Lux Q3 2025 Report Josh Wolfe October 28, 2025 Lux Capital's 3rd
Cognition Therapeutics Appoints Industry Veteran Jack Khattar to its Board of Directors – Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Overview Press Releases Events In The News Financial Information Stock Information Corporate Governance FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting Ops About Us About Us Management Team Board of Directors Advisory Boards Investors Overview Press Releases Events In The News Financial … -person Phase 2 study in collaboration with ACTC and supported by a competitive grant from the National Institute on Aging. Additional information about Cognition and its product candidates may be found online at www.cogrx.com . Linkedin-in X-twitter Terms of Use Privacy Policy Careers FCOI Policy Contact us Copyright© 2025 Cognition Therapeutics All rights reserved Scroll to Top Thank you for your interest in Cognition’s publications. A PDF of the poster you are intere
AI-Native Software Development Arrives with Cognition Partnership | Improving posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, y
Cognition Therapeutics holders back directors, auditor | CGTX 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks O … l Meeting Broker non-votes on directors 34,035,661 votes Each Class II director proposal Votes for auditor ratification 49,039,407 votes Ratification of Ernst & Young LLP for 2026 fiscal year Votes against auditor ratification 126,951 votes Ratification of Ernst & Young LLP for 2026 fiscal year Abstentions on auditor ratification 643,517 votes Ratification of Ernst & Young LLP for 2026 fiscal year Key Terms Annual Meeting of Stockholders, broker non-votes, indepen … tage product with fewer user reviews. Election of Class II Directors financial "Proposal 1 – Election of Class II Directors." See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google Add on Google Not now Understanding 8-K Material Events → Available on EDGAR 06/18/2026 - 08:05 AM Accepted by SEC EDGAR 06/18/2026 - 08:05 AM Learn about SEC filing dates ⛶ Fullscreen false 0001455365 0001455365 2026-06-17 2026-06 … ith the U.S. Securities and Exchange Commission on April 27, 2026 .   Proposal 1 – Election of Class II Directors. Each of Aaron Fletcher, Ph.D., and Lisa Ricciardi were elected to the Board of Directors as Class II directors to serve until the Company’s 2029 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal as follows:   … 35,661 Lisa Ricciardi   15,094,238   679,976   34,035,661   Proposal 2 – Ratification of Independent Registered Public Accountants. The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was ratified, as follows:   For   Agains
Cognition Therapeutics Appoints Brett P. Monia to its Board of Directors | Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting OPS About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial In … -person Phase 2 study in collaboration with ACTC and supported by a competitive grant from the National Institute on Aging. Additional information about Cognition and its product candidates may be found online at www.cogrx.com. View All Press Releases Investor Relations Contact Cognition Therapeutics [email protected] Mikey Moyer LifeSci Advisors [email protected] Email Alerts Email I accept the Privacy Policy Submit Unsubscribe Loading... Linkedin-in X-twitter Terms of
Press Releases | Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting OPS About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipe … isors [email protected] Email Alerts Email I accept the Privacy Policy Submit Unsubscribe Loading... Linkedin-in X-twitter Terms of Use Privacy Policy Careers FCOI Policy Contact us Copyright© 2024 Cognition Therapeutics All rights reserved Scroll to Top Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. You are n
Board of Directors – Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Overview Press Releases Events In The News Financial Information Stock Information Corporate Governance FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting Ops About Us About Us Management Team Board of Directors Advisory Boards Investors Overview Press Releases Events In The News Financial Information Stock Information Corporate Governance FAQs Pipeline Pip
Infosys partners with Cognition to expand engineering capacity and help scale its enterprise business | Cognition Menu Close Home Careers Research Blog Contact Devin Home Careers Research Blog Contact Devin Infosys partners with Cognition to expand engineering capacity and help scale its enterprise business By The Cognition Team 01.07.26 Infosys, a global leader in digital services and consulting, has partnered with Cognition to deploy Devin , the AI software engineer, across its organization and global client base. By augmenting its workforce with autonomous software engineers, Infosys will d … orld’s most complex and regulated enterprise environments. Infosys has begun by rolling out Devin in its Financial Services practice, across banking, payments, capital markets, insurance, and wealth management use cases—both within its own teams and inside customer organizations. Then, the rollout is aimed towards expanding to retail, energy, healthcare, and other verticals where Infosys operates. Over the past six months, Infosys has unlocked material productivity gains with
Sofia Fund Portfolio Earns Returns as Two Portfolio Companies Move to Next Stage of Growth - Sofia Fund Focus Criteria Team Investments Resources News Contact × --> Focus Criteria Team Investments Resources News Contact Menu --> Sofia Fund Portfolio Earns Returns as Two Portfolio Companies Move to Next Stage of Growth by Sofia Fund | Oct 25, 2021 | Portfolio Company News Cognitive Therapeutics goes public, Explorer Surgical acquired MINNEAPOLIS (Oct. 25, 2021) – Sofia Fund, the angel investment firm focused exclusively on women-led companies, announces new milestones: two of its p … stock is now listed on The Nasdaq Global Market under the symbol “CGTX.” Sofia Fund made three investments in Pittsburgh-based CGTX, recognizing the strength of the company’s diverse leadership team and its vision to solve an unmet need in the marketplace. Explorer Surgical Corp. (Explorer Surgical), which provides digital and remote case support platforms that connect medical device suppliers with healthcare provider teams inside the operating room, has been acquired by Glo … deliver patient care. Chicago-based Explorer Surgical became part of the Sofia Fund portfolio in March 2021. “Both of these companies demonstrate the demand for health and wellness technology and are examples of well-managed, high-growth businesses run by women,” said Cathy Connett, managing partner of Sofia Fund and an experienced investor in early stage companies. “These are big wins for these entrepreneurs and the growing community of women investing in other women.” Sofi … trepreneurs and the growing community of women investing in other women.” Sofia Fund was one of the first investment groups to focus exclusively on gender-diverse startups and has brought many women into the asset class of angel investing. It concentrates its investments in the IT, enterprise solutions, technology, and health and wellness sectors. About Sofia Fund Sofia Fund invests in exceptional women-led companies to maximize returns for investors by helping to bring its p … elping to bring its portfolio companies successfully to profitable exits. Sofia Fund uses a rigorous process for selecting and investing in high-growth, technology-driven opportunities. Its team of professional women angel investors actively manages and supports its portfolio businesses, leveraging deep expertise and broad networks to help women
Cognition and Collaboration Systems Group | NIST Skip to main content An official website of the United States government Here’s how you know Here’s how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites. https://www.nist.gov/el/intelligent-systems-division-73500/cognition-and-collaboration-systems Search NIST Menu Close Publications What W … eras, and radars, to ensure... View All Publications Awards 2023 - Bronze Medal Award---Joe Falco, Kenneth Kimble, Megan Zimmerman, Justin Albrecht For developing widely adopted assembly task boards and innovative robotic competitions to advance automation solutions for U.S. manufacturers. Craig Schlenoff Receives Washington Academy of Sciences 2023 Leadership Award in Manufacturing Engineering To recognize an individual in the government or industry for outstanding leadershi … ormance monitoring sensor and test method to manufacturers. 2021 - Bronze Medal Award---Craig Schlenoff, William Harrison, Anthony Downs, Pavlo Piliptchak, Murat Aksu For developing an innovative simulation-based robot agility competition that has spurred breakthrough solutions to industry’s robotics challenges. View All Awards Was this page helpful? HEADQUARTERS 100 Bureau Drive Gaithersburg, MD 20899 301-975-2000 Webmaster | Contact Us | Our Other Offices X.com Facebook Lin
Cognition VC Portfolio Companies & Investment Focus | InvestorMatch.pro Investor Match How It Works Pricing Explore Investors For Investors Blog About VC Firms Cognition VC CO Cognition VC VC San Francisco, CA Website How to approach: warm intro preferred Start a Campaign Explore Similar Investors Stage Pre-Seed, Seed Check Size $500K – $2.5M Portfolio 2+ companies Team 3 partners Investor activity Investments in last 12 months: 0 Investment Thesis Cognition VC specializes in B2B SaaS and automation startups leveraging artificial intelligence to enhance enterprise workflows. Meet the Team
Alpha Cognition Inc. - Building new Transformative Treatments for Alzheimer’s and ALS --> Corporate About ACI Executive Team Board of Directors Our People Scientific Advisory Board Our Focus ZUNVEYL® (benzgalantamine) Alzheimer's Disease Cognitive Impairment with Mild Traumatic Brain Injury Our Pipeline Investors Stock Info News Financials and Filings Analyst Coverage Events & Presentations Investor Relations Contact Governance Annual General Meeting Business Development Contact Careers --> Menu Corporate About ACI Executive Team Board of Directors Our People Scientific Advisory Board Our Focu … 3872 High 9.91 Low 9.67 Stock Information Sign up to receive our latest updates Submit Investor Relations N PJ Kelleher, LifeSci Advisors P 905 326 1888 Ext 6 --> E [email protected] E [email protected] Social Media --> Corporate About ACI Executive Team Board of Directors Our People Scientific Advisory Board Our Focus ZUNVEYL® (benzgalantamine) Alzheimer's Disease Cognitive Impairment with Mild Traumatic Brain Injury Our Pipeline Investors Stock Info News Fin
Cognition Therapeutics Elects Lisa Ricciardi to its Board of Directors | Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting OPS About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Info … t of Neurological Function with Elayta). These studies are supported by grants (award numbers RF1AG057780, RF1AG057553 and R01AG058660) from the National Institute on Aging of the NIH. Elayta has been granted Fast Track designation by the U.S. FDA. Elayta and Cognition’s other pipeline candidates were identified using the company’s disease-relevant screening and novel chemistry platforms. Additional information about Cognition and its product candidates may be found online at … isors [email protected] Email Alerts Email I accept the Privacy Policy Submit Unsubscribe Loading... Linkedin-in X-twitter Terms of Use Privacy Policy Careers FCOI Policy Contact us Copyright© 2024 Cognition Therapeutics All rights reserved Scroll to Top Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. You are n
LSINW Sponsorship Landing Page | Health & Life Science Brand & Product Strategy Studio — Seattle | Cognition Studio Skip to content Health & Life Science Brand & Product Strategy Studio — Seattle | Cognition Studio Menu Work Capabilities Overview Science Visualization Brand Identity & Design Systems Web & Digital Innovation Strategic Communications About Meet the team Life at Cognition Contact Seattle’s top science communication firm The best scientific ideas have the power to change the world, but only when concepts can translate into impact. Accomplishing that goal
Language and Cognition | Department of Linguistics | University of Colorado Boulder Skip to main content Department of Linguistics Home Linguistics Office and Support People Research Undergraduate Program Graduate Program Prospective Students News & Events Courses Donate Careers Graduate Diversity Fall 2025, Spring & Summer 2026 Graduates Graduation 2026 Translate English Spanish Chinese French German Korean Lao Nepali Japanese Tibetan Search Enter the terms you wish to search for. Other ways to search: Events Calendar Campus Map Department of Linguistics College of Arts and Sciences Home Ling
Cognizant and Cognition Partner to Scale Autonomous Software Engineering and Deliver Business Value Across Enterprise Operations - Jan 28, 2026 Skip to main content Skip to footer --> Cognizant.com Industries Services Latest Thinking Type in a topic service or offering and then hit Enter to search Common Searches : Close Cognizant Newsroom News announcements Cognizant in the news Resources Insights Blog Awards Investor Relations Cognizant Newsroom News announcements Cognizant in the news Resources Insights Blog Awards Investor Relations Cognizant.com Industries Services Latest Thinking X … ion, creator of Devin AI, the autonomous software engineer, to help enterprises apply AI to software development work at scale. Unlike traditional coding assistants that suggest code, Devin can take on end-to-end development tasks independently, planning, executing and validating work across complex systems. Together, Cognizant and Cognition will bring these capabilities into enterprise environments, pairing advanced AI with the governance, platforms and operational scale req … enterprises modernize applications faster, improve engineering productivity and apply AI across activities such as code migration and refactoring, testing and quality engineering, and ongoing application maintenance. "AI is fundamentally transforming how software is built. At Cognizant, 30 percent of our code is already generated with AI, and we aim to reach 50 percent in the near future. But achieving this requires more than powerful models or tools," said Ravi Kum … tail Transportation & Logistics Travel & Hospitality Utilities Services Application Services & Modernization Artificial Intelligence Business Process Services Cloud Solutions Core Modernization Digital Experience Digital Strategy Enterprise Application Services Infrastructure Services Intelligent Process Automation Internet of Things Quality Engineering & Assurance Security Software Product Engineering Sustainability Services Consulting Insights Themes Modern
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812) | Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting OPS About Us About Us Management Team Board of Directors Advisory Boards Investors Inv … t limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and ea … isors [email protected] Email Alerts Email I accept the Privacy Policy Submit Unsubscribe Loading... Linkedin-in X-twitter Terms of Use Privacy Policy Careers FCOI Policy Contact us Copyright© 2024 Cognition Therapeutics All rights reserved Scroll to Top Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. You are n
Touch A Truck Sponsors | Cognition 119 North Salisbury St. Mocksville NC 27028 (336) 753-1045 [email protected] VIEW CALENDAR UPCOMING EVENTS My Account Donate HOME ABOUT WHO WE ARE OUR SPACE MEET THE BOARD MEET THE STAFF EDUCATION & PROGRAMS CAMPS SUMMER CAMPS FIELD TRIPS HOMESCHOOL PROGRAMMING STEAM STORYTIME LITTLE SPARKS STEAM ACADEMY MIDDLE SCHOOL PROGRAMMING CALENDAR VISIT Hours and Admission Memberships Summer Play Passes GIFT CARDS UPCOMING EVENTS BIRTHDAY PARTIES Sensory Friendly Visits Touch-A-Truck Become A Sponsor 2025 Touch A Truck Sponsors SUPPORT Support Cognition CON
Windsurf Got Acquired by Cognition for $3B — Is the AI IDE Market Already Consolidating? - General - 10x.pub 10x.pub Windsurf Got Acquired by Cognition for $3B — Is the AI IDE Market Already Consolidating? General eng_director_luis February 11, 2026, 8:26pm 1 I’ve been sitting with this news for a couple of weeks now, and I think it’s worth unpacking what the Cognition-Windsurf deal means for those of us trying to make responsible tooling decisions at scale. The Deal In early 2025, Cognition — the company behind Devin, which they market as an “AI software engineer” — acquired Windsurf (formerl … vider. 2. Shorten evaluation cycles. Six months was too long. We’re moving to a rolling evaluation model where we do lighter-weight assessments quarterly and allow teams to experiment with different tools in sandboxed environments. 3. Watch the integration patterns. What happens to Windsurf’s data practices, pricing model, and feature roadmap under Cognition will tell us a lot about how these acquisitions play out. It’s a useful case study even if we don’t end up using the pr
Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022 | Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting OPS About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Eve … ely $52 million. $45 million in NIA grants: Cognition was awarded a $30 million grant from the National Institute on Aging (NIA) to support a planned Phase 2 study of CT1812 in dementia with Lewy bodies (DLB). The company received additional grant funding from the NIA to conduct human absorption, metabolism, and excretion (hAME) studies ($1.6 million) and to supplement the ongoing Phase 2 SHINE (COG0201) study of CT1812 ($13.6 million). In 2020, Cognition experienced a tempor … assessing cognition and biomarkers. This trial is funded by an NIA $81 million grant. Enroll the final cohort in the ongoing SHINE trial recruiting 120 patients with mild-to-moderate Alzheimer’s disease. An interim analysis demonstrated a clinically meaningful three-point change in ADAS-COG scores at day 185, and a statistically significant reduction in Aβ protein in the treated arm. This study is supported by a $30 million grant from the NIA. Expand the pipeline with Phase … 2 dry AMD study and DLB studies, the latter of which is funded by a $30 million grant from NIA. Advance preclinical work in Parkinson’s disease evaluating two σ-2 modulators for clinical development. This project is partially funded by a grant from the Michael J. Fox Foundation. Beginning today, Cognition Therapeutics is participating in one-on-one meetings during the week of the annual JP Morgan Healthcare Conference, January 10-14, 2022, and will present on a panel at the B … isors [email protected] Email Alerts Email I accept the Privacy Policy Submit Unsubscribe Loading... Linkedin-in X-twitter Terms of Use Privacy Policy Careers FCOI Policy Contact us Copyright© 2024 Cognition Therapeutics All rights reserved Scroll to Top Thank you for your interest in Cognition’s publications. A PDF of the poster y
Become a Sponsor – Creativity & Cognition 2023 Skip to content Home Submit Papers Pictorials Artworks Workshops Tutorials Posters Technical Demonstrations Graduate Student Symposium Undergraduate Research Attend Registration Workshops Program Keynote Speakers Sponsors Become a Sponsor Adobe Organizing Organizing Committee Student Volunteers: Call for Participation For Authors Publishing Your Accepted C&C’23 Submission Video Presentation Instructions Past Conferences Navigation Menu Navigation Menu Home Submit Papers Pictorials Artworks Workshops Tutorials Posters Technical Demon
Enterprise data search and analytics. Acquired by Spark Cognition - Aramco Ventures Menu Home Portfolio News Team Affiliated Programs Contact Enterprise data search and analytics. Acquired by Spark Cognition HEADQUARTERS Al-Midra Tower, 11th Floor, West Wing, Dhahran 31311 Kingdom of Saudi Arabia Copyright © 2025 Aramco Ventures Privacy Policy Terms of use
Cognition Therapeutics Extends IP Coverage of Alzheimer’s Therapeutic Elayta™ to Additional Major Pharmaceutical Markets with Patent Issuances in Japan and China | Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting OPS About Us About Us Management Team Board of Directors A … t of Neurological Function with Elayta). These studies are supported by grants (award numbers RF1AG057780, RF1AG057553 and R01AG058660) from the National Institute on Aging of the NIH. Elayta has been granted Fast Track designation by the U.S. FDA. Elayta and Cognition’s other pipeline candidates were identified using the company’s disease-relevant screening and novel chemistry platforms. Additional information about Cognition and its product candidates may be found online at … isors [email protected] Email Alerts Email I accept the Privacy Policy Submit Unsubscribe Loading... Linkedin-in X-twitter Terms of Use Privacy Policy Careers FCOI Policy Contact us Copyright© 2024 Cognition Therapeutics All rights reserved Scroll to Top Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. You are n
Impact of e-cigarette advertising, promotion, and sponsorship on cognition and behavior: a systematic review of public responses Impact of e-cigarette advertising, promotion, and sponsorship on cognition and behavior: a systematic review of public responses BMC Health Serv Res . 2025 Dec 24;26(1):135. doi: 10.1186/s12913-025-13929-6. Authors Atchara Prajongjeep 1 , Thanavutd Chutiphongdech 2 , Kornkan Phuengnam 3 , Thitiporn Sukaew 1 , Theeraphon Lopradit 1 , Yutthana Yeabkai 1 Affiliations 1 Faculty of Public Health and A
S-1 1 tm2113659-6_s1.htm S-1 tm2113659-6_s1 - none - 31.2189295s TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 19, 2021. Registration No. 333-       ​ ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cognition Therapeutics, Inc. (Exact name of registrant as specified in its charter) ​ Delaware ​ ​ 2836 ​ ​ 13-4365359 ​ ​ (State or other jurisdiction of incorporation or organiz … and Drug Administration, or the FDA, in this indication. With the support of a grant of approximately $81.0 million from the NIA, we intend to enroll 540 patients in our COG0203 clinical trial with mild cognitive impairment, or MCI, due to AD or mild AD who have elevated levels of Aβ as determined by positron emission tomography, or PET, imaging or as measured in cerebral spinal fluid, or CSF. Patients will be randomized to receive CT1812 or a placebo for 18 m … iated with early-stage AD in the first half of 2022, which has been funded by a grant award of approximately $81.0 million from the NIA. ​ • Pursue the development of CT1812 for dry AMD . We plan to evaluate CT1812 as a potential therapy for dry AMD, a common eye disease that results in the deterioration of the macula, causing visual distortion, loss of central vision and eventual blindness. We believe that an S2R antagonist, such as CT1812, … 160;million in cumulative grants awarded primarily by the NIA, which includes a grant award of approximately $81.0 million from the NIA to fund our upcoming Phase 2 (COG0203) study of CT1812 in patients with early-stage AD. These grants are non-dilutive and allow us to collaborate with research institutions in pursuing the development of our product candidates for age-related degenerative diseases. We intend to continue our work with these research institutions and … the adoption of some accounting standards until those standards would otherwise apply to private companies.   5 TABLE OF CONTENTS   We will remain an emerging growth company until the earliest of (1) the last day of the fiscal year following the fifth anniversary of the closing of this offering, (2) the last day of the fiscal
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes | Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting OPS About Us About Us Management Team Board of Directors Advisory Boards In … gnment with the Company on key aspects of a pivotal trial to support a New Drug Application (NDA). The registrational program is expected to begin in mid-2027. As discussed with the FDA, Cognition expects the Phase 3 study will enroll people with DLB who experience psychosis symptoms of hallucinations and delusions. Patients receiving stable background treatment with off-label antipsychotic medications will be eligible. Following screening, participants will be randomized to … re not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and ea … isors [email protected] Email Alerts Email I accept the Privacy Policy Submit Unsubscribe Loading... Linkedin-in X-twitter Terms of Use Privacy Policy Careers FCOI Policy Contact us Copyright© 2024 Cognition Therapeutics All rights reserved Scroll to Top Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. You are n
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trend … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies January 28, 2026 | 6 min read Twitter LinkedIn Facebook Email Print PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a c … udy ( NCT05531656 ) in early Alzheimer’s disease is ongoing with $81 million in grant support from the National Institute of Aging (NIA) at the National Institutes of Health. We believe zervimesine can regulate pathways that are impaired in these diseases though its interaction with the sigma-2 receptor, a mechanism that is functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at … re not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and ea … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect inn
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies February 5, 2026 | 7 min read Twitter LinkedIn Facebook Email Print PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a … re not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and ea … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update May 8, 2026 | 8 min read Twitter LinkedIn Facebook Email Print Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational plans for zervimesine in DLB psychosis PU … ents as of March 31, 2026 were approximately $31.2 million, and total obligated grant funds remaining from the National Institute of Aging, a division of the National Institute of Health were $25.6 million. The Company estimates that it has sufficient cash to fund operations and capital expenditures through the second quarter of 2027. Research and development expenses were $6.1 million for the quarter ended March 31, 2026, compared to $10.8 million for the comparable period i … re not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and ea … sp; (13,775 ) Other income (expense): Grant income 3,979 5,086 Other income, net 273 214 Interest expense (5 ) (5 ) Total other income, net 4,247 5,295 Net loss and comprehensive l
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045 June 16, 2026 | 7 min read Twitter LinkedIn Facebook Email Print PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the “Compa … received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468. The allowed patent covers a polymorphic crystalline form of zervimesine (CT1812), the company's lead drug candidate. Once issued, the patent will provide protection for this key formulation through 2045 and, if granted a standard 5-year extension, could offer protection through 2050. Titled “Crystalline forms of 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindol … l-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol fumarate salt,” this patent application covers: Composition of Matter: a polymorphic crystalline form of zervimesine. Production Process: A specialized, proprietary process for producing zervimesine. Therapeutic Methods: Methods of treating highly underserved, age-related degenerative disorders including Alzheimer’s disease, geographic atrophy, and dementia with Lewy bodies (DLB). While containing the same molecular componen … re not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies a
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 March 17, 2026 | 8 min read Twitter LinkedIn Facebook Email Print PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cog … re not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and ea … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Business Takeda enters transitional year as new CEO seeks return to growth June 24, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities an … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business J … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis May 21, 2026 | 6 min read Twitter LinkedIn Facebook Email Print - Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cogniti … re not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and ea … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newslett … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Bus … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs August 8, 2025 | 9 min read Twitter LinkedIn Facebook Email Print - Discussed plans to support a pivotal Alzheimer’s disease program with FDA at end-of-phase 2 meeting - - Initiate … alents as of June 30, 2025 were approximately $11.6 million and total obligated grant funds remaining from the National Institute of Aging, a division of the National Institute of Health were $41.9 million. The Company estimates that it has sufficient cash to fund operations and capital expenditures into the second quarter of 2026. Research and development expenses were $11.5 million for the quarter ended June 30, 2025, compared to $11.6 million for the comparable period in 2 … udy ( NCT05531656 ) in early Alzheimer’s disease is ongoing with $81 million in grant support from the National Institute of Aging (NIA) at the National Institutes of Health. We believe zervimesine can regulate pathways that are impaired in these diseases though its interaction with the sigma-2 receptor, a mechanism that is functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at … re not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies a
Cognition Therapeutics Participating in Upcoming June 2026 Investor Conferences - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cognition Therapeutics Participating in Upcoming June 2026 Investor Conferences June 1, 2026 | 6 min read Twitter LinkedIn Facebook Email Print PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerat … re not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and ea … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy C … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences September 3, 2024 | 4 min read Twitter LinkedIn Facebook Email Print PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company … re not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities and costs related thereto; uncertainties related to the conduct and results of clinical trials; the timing, scope and likelihood of regulatory filings and … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cognition Therapeutics to Present Corporate and Clinical Update at H.C. Wainwright Global Life Sciences Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job T … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country Cognition Therapeutics to Present Corporate and Clinical Update at H.C. Wainwright Global Life Sciences Conference March 3, 2021 | 2 min read Twitter LinkedIn Facebook Email Print Cognition Therapeutics, Inc. , a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by … -person Phase 2 study in collaboration with ACTC and supported by a competitive grant from the National Institute on Aging. Additional information about Cognition and its product candidates may be found online at www.cogrx.com . Cautionary Statement Regarding Forward Looking Statements This press release contains forward-looking statement, including those concerning the development and commercialization of Cognition Therapeutics’ product candidates and pipeline, their potenti … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Sigma-2 Modulation - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Sigma-2 Modulation November 30, 2021 | 4 min read Twitter LinkedIn Facebook Email Print Cognition Therapeutics, Inc. will hold a virtual R&D symposium on December 7, 2021, from 10:00am … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cognition Therapeutics CEO Issues Letter to Shareholders - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cognition Therapeutics CEO Issues Letter to Shareholders April 1, 2026 | 8 min read Twitter LinkedIn Facebook Email Print Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second … ormative for us. As a reminder, the START trial has been fully funded by an NIH grant and costs are covered through the completion of the study in 2027. Once we see the final results from this trial in the second half of 2027, we will assess next steps for the treatment of Alzheimer’s disease. Looking Ahead Thank you for your continued support as we pursue this mission together. With the momentum of 2025’s achievements, I am confident that 2026 will bring zervimesine one step … re not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and ea … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cognition Therapeutics CEO Issues Letter to Shareholders - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country Cognition Therapeutics CEO Issues Letter to Shareholders January 4, 2024 | 10 min read Twitter LinkedIn Facebook Email Print Cognition Therapeutics, Inc. today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the com … re not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and ea … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
so… Havana got acquired by Cognition! i joined havana when it was only the two founders. immediately, it was obvious just how great they were as operators. but amidst their story of success, i… | Grace Kong LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time
Pipeline – Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Overview Press Releases Events In The News Financial Information Stock Information Corporate Governance FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting Ops About Us About Us Management Team Board of Directors Advisory Boards Investors Overview Press Releases Events In The News Financial Information Stock Information Corporate Governance FAQs Pipeline Pipeline Alzh
Cognition Therapeutics Completes Oversubscribed $12 Million Series B Financing – Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Overview Press Releases Events In The News Financial Information Stock Information Corporate Governance FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting Ops About Us About Us Management Team Board of Directors Advisory Boards Investors Overview Press Releases Events In The News Financial Informat … nces investors. Existing CogRx investors, including Ogden CAP, PLSG Accelerator Fund, Tech Coast Angels, ACE Fund, Ariel Southeast Angel Partners and M5Invest Partners also participated in the financing. “This latest round of financing is indicative of the growing commitment we are seeing from investors to find new and effective treatments for Alzheimer’s disease,” said Dr. Hank Safferstein, Chief Executive Officer. “We are emboldened by the recen
Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update | Cognition Therapeutics, Inc. Skip to content About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events In The News Financial Information Corporate Governance Stock Information FAQs Pipeline Pipeline Alzheimer’s Disease CT1812 MoA Video Dementia with Lewy Bodies Publications Clinical Trials Conversations Contracting OPS About Us About Us Management Team Board of Directors Advisory Boards Investors Investor Overview Press Releases Events … tion (MJFF) that have provided substantial funding of our research. Our NIA DLB grant remains the largest NIA award to fund a study in DLB, which provides the validation and generous support to continue our trial,” added Ms. Ricciardi. “We are excited about our future and remain committed to our goal of finding treatments for these degenerative diseases.” Business Updates: Dosing commenced in the second cohort of the Phase 2 SHINE study in Alzheimer’s disease. Site selection … elium (RPE) cells and normalize key homeostatic processes disrupted in dry AMD. Award from MJFF to support preclinical development of pipeline molecules for the treatment of synucleinopathies. Strong balance sheet with $51.5 in cash and cash equivalents and substantial grant funding as of March 31, 2022. At the beginning of the year, the Company had remaining available and awarded grant funding of approximately $110 million. Q1 2022 Financial Results: Research and development … ded from sponsor partners, the Company estimates that it has sufficient cash to fund operations and capital expenditures into the second half of 2023. About Cognition Therapeutics, Inc. Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidat … Other income (expense): Grant income 5,904 4,692 Change in the fair value of the derivative liability — 1,063 Other (expense) income, net (195 ) 145 Gai
CerraCap Ventures portfolio company Nirveda Cognition acquired by Jiddu Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedi … if. , Aug. 13, 2021 /PRNewswire/ -- CerraCap Ventures, a Global Venture Capital fund headquartered in Costa Mesa, California , USA, today announced acquisition of its portfolio company Nirveda Cognition by Jiddu Inc for an all-stock deal. The transaction is one of a slew of recent exits from CerraCap's investment fund. Nirveda Cognition, a B2B Enterprise AI company, was founded on the core belief that unprecedented problems require unprecedented solutions, and technologies li … er, Jiddu . About CerraCap Ventures CerraCap Ventures, a Global Venture Capital fund headquartered in Southern California , dedicated to early-stage technology investments in enterprise (B2B) solutions focused on the new fundamentals of the digital age - Enterprise AI, Cyber Security and Healthcare. It enables rapid growth of technology startups leveraging its unique Sales & Scale ™ business model, driving revenue from large enterprises into its portfolio comp … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB) - The Globe and Mail Home Canada Business Investing Life Opinion World Politics Personal Finance Culture Sports More More Latest in More Real Estate Drive Watchlist For You Events Find clarity in the chaos. Subscribe now and save 70% Subscribe Digital access Digital + home delivery TSX -0.55 % S&P 500 -0.1 % DOW 0.35 % NASDAQ -0.43 % Oil -1.08 % Dollar -0.01 % Gold -0.24 % tsx movers: CNQ-T -3.69 % T-T -1.72 % WCP-T -4.59 % SU-T -3.4 % This section contains … I, an objective assessment of parkinsonism. The SHIMMER study is supported by a grant award from the National Institute on Aging of the National Institutes of Health (NIH) totaling approximately $30 million and is being conducted in collaboration with James E. Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and the Lewy Body Dementia Association (LBDA). The SHIMMER study is being conducted at over 30 … re not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and ea … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Registry Modern Slavery Report AI Guidelines Subscribe Digital + Home Delivery Digital Access Globe2Go The New York Times Globe Email … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Re
Cognition Therapeutics (CGTX) Latest News & Stock Updates - Page 2 Skip to main Stocks Options ETFs Crypto Bonds High-Yield Cash Account API Agents More About Us Learn Support Sign In Get Started About CGTX Market cap P/E ratio Forecast Earnings News Pre-market After-hours CGTX • News Stocks Cognition Therapeutics News CGTX Volume: 45.68K Cognition Therapeutics (CGTX) Latest News & Updates Explore latest Cognition Therapeutics (CGTX) News and Updates Stay updated on Cognition Therapeutics (CGTX) with the latest news, market trends, and key developments to support informed investing dec … T1812) in Alzheimer's Disease GlobeNewsWire • 08/12/25 Cognition (CGTX) Q2 Grant Income Jumps The Motley Fool • 08/08/25 Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease GlobeNewsWire • 07/29/25 Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease GlobeNewsWire • 0 … during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Public’s Investing’s Fee Schedule to learn more. Fractional shares are illiquid outside of Public and not transferable. For a complete explanation of conditions, restrictions and limitations associated with fractional shares, see our Fractional Share Disclosure to learn more. Investment Plans. Investment Plans (“Plans”) shown in our marketplace are for i